Castle Biosciences (CSTL) Income from Continuing Operations (2018 - 2026)
Castle Biosciences (CSTL) posted Income from Continuing Operations of 2060000.0 for Q2 2026, up 85.81% sequentially from 14522000.0 in Q1 2026, and down 145.21% YoY from 4557000.0 in Q2 2025.
Castle Biosciences (CSTL) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Castle Biosciences has reported Income from Continuing Operations for 9 years, with the latest figure at 2060000.0 in Q2 2026.
- Quarterly Income from Continuing Operations fell 145.21% year-over-year to 2060000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 19415000.0 (down 105.84% YoY) and the FY2025 annual result came in at 24158000.0, down 232.41% from the prior year.
- Income from Continuing Operations climbed to 2060000.0 in Q2 2026 per CSTL's latest filing, from 14522000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 9590000.0 in Q4 2024 and troughed at 29204000.0 in Q1 2023.
- A 5-year average of 8170277.78 and a median of 2557000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations slumped 1039.38% in 2023, then surged 471.71% in 2024.
- Over 5 years, Income from Continuing Operations stood at 20618000.0 in 2022, then jumped by 87.49% to 2580000.0 in 2023, then soared by 471.71% to 9590000.0 in 2024, then sank by 124.32% to 2332000.0 in 2025, then increased by 11.66% to 2060000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 2060000.0, 14522000.0, and 2332000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 234.15 Bn | 230.09 Bn | 8.34 Bn | 1.76 Bn |
| 2 | Danaher | 152.10 Bn | 147.75 Bn | 3.61 Bn | 870.00 Mn |
| 3 | Natera | 48.48 Bn | 47.38 Bn | 486.15 Mn | -66.93 Mn |
| 4 | Agilent Technologies | 44.35 Bn | 42.55 Bn | 990.00 Mn | 339.00 Mn |
| 5 | Iqvia Holdings | 43.68 Bn | 41.60 Bn | 1.44 Bn | 241.00 Mn |
| 6 | Idexx Laboratories | 43.02 Bn | 42.83 Bn | 779.09 Mn | 338.41 Mn |
| 7 | Illumina | 34.39 Bn | 33.22 Bn | 770.00 Mn | 207.00 Mn |
| 8 | Mettler Toledo International | 28.29 Bn | 28.24 Bn | 650.22 Mn | 232.90 Mn |
| 9 | Labcorp Holdings | 27.51 Bn | 27.37 Bn | 1.11 Bn | 299.10 Mn |
| 10 | Castle Biosciences | 1.04 Bn | 773.13 Mn | 79.85 Mn | -2.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.06 Mn |
| Mar 31, 2026 | -14.52 Mn |
| Dec 31, 2025 | -2.33 Mn |
| Sep 30, 2025 | -501,000.00 |
| Jun 30, 2025 | 4.56 Mn |
| Mar 31, 2025 | -25.85 Mn |
| Dec 31, 2024 | 9.59 Mn |
| Sep 30, 2024 | 2.27 Mn |
| Jun 30, 2024 | 8.92 Mn |
| Mar 31, 2024 | -2.53 Mn |
| Dec 31, 2023 | -2.58 Mn |
| Sep 30, 2023 | -6.91 Mn |
| Jun 30, 2023 | -18.78 Mn |
| Mar 31, 2023 | -29.20 Mn |
| Dec 31, 2022 | -20.62 Mn |
| Sep 30, 2022 | -20.25 Mn |
| Jun 30, 2022 | -1.65 Mn |
| Mar 31, 2022 | -24.62 Mn |
| Dec 31, 2021 | -13.38 Mn |
| Sep 30, 2021 | -11.79 Mn |